瑞马唑仑与丙泊酚在高危患者上消化道内镜检查中的效果:一项非劣效性随机对照试验
计划纳入576例高危上消化道内镜检查患者,随机分为瑞马唑仑组或丙泊酚组,主要终点为复合终点(MOAA/S评分≤3、操作成功、无显著呼吸不稳定、无显著循环不稳定),非劣效界值为10%。试验旨在确定瑞马唑仑在成功率、并发症发生率、患者舒适度和满意度方面是否非劣效于丙泊酚。
要点
- 计划纳入576例高危上消化道内镜检查患者,随机分配至瑞马唑仑组或丙泊酚组。
- 主要终点为复合终点,非劣效界值为10%。
- 试验旨在评估瑞马唑仑在成功率、并发症、舒适度和满意度方面是否非劣效于丙泊酚。
核心结论
- 该试验旨在确定瑞马唑仑在高危患者上消化道内镜检查的程序性镇静中,在成功率、并发症发生率、患者舒适度和满意度方面是否非劣效于丙泊酚。
研究设计与样本
- 非劣效性随机对照试验,计划纳入576例拟行上消化道内镜检查的高危患者,随机分配至瑞马唑仑组或丙泊酚组。
关键数值与推荐
- 主要终点为复合终点,包括内镜插入前改良观察者警觉/镇静评分(MOAA/S)≤3分、内镜操作成功完成、检查治疗期间无显著呼吸不稳定、检查期间无显著循环不稳定。
- 非劣效界值为10%。
- 将报告发生的任何不良事件(AEs)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Procedural sedation is essential for optimizing upper gastrointestinal endoscopy, particularly in high-risk patients with multiple underlying diseases. Respiratory and circulatory complications present significant challenges for procedural sedation in this population. This non-inferiority randomized controlled trial aims to investigate the safety and comfort of remimazolam compared to propofol for procedural sedation during upper gastrointestinal endoscopy in high-risk patients. METHODS: A total of 576 high-risk patients scheduled to undergo upper gastrointestinal endoscopy are planned to be enrolled in this study and randomly allocated to either the remimazolam or propofol group. The primary outcome measure is a composite endpoint, which includes (1) achieving a Modified Observer's Alertness/Sedation scale (MOAA/S) score ≤ 3 before endoscope insertion, (2) successful completion of the endoscopic procedure, (3) the absence of significant respiratory instability during the endoscopy and treatment, and (4) the absence of significant circulatory instability during the examination. The noninferiority margin was 10%. Any adverse events (AEs) that occur will be reported. DISCUSSION: This trial aims to determine whether remimazolam is non-inferior to propofol for procedural sedation during upper gastrointestinal endoscopy in high-risk patients, regarding success rate, complication incidence, patient comfort, and satisfaction. TRIAL REGISTRATION {2A AND 2B}: Chinese Clinical Trial Registry ClinicalTrials.gov ChiCTR2200066527. Registered on 7 December 2022.
引用
- Li Z, Yuan D, Yu Y, et al. Effect of remimazolam vs propofol in high-risk patients undergoing upper gastrointestinal endoscopy: a non-inferiority randomized controlled trial. Trials. 2024. PMID: 38281035. doi:10.1186/s13063-024-07934-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。